Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen, Inc.

http://www.amgen.com

Latest From Amgen, Inc.

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Clinical Trials Business Strategies

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.

Strategy Sales & Earnings

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Research & Development Innovation

Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation

CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.

Drug Safety ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Abgenix
    • Amgen Astellas BioPharma K.K.
    • Amgen K.K.
    • Avidia
    • BioVex Group
    • Catherex, Inc.
    • ChemoCentryx, Inc.
    • deCODE Genetics
    • Dezima Pharma B.V.
    • Five Prime Therapeutics, Inc.
    • Ilypsa
    • Immunex Corporation
    • KAI Pharmaceuticals
    • Kirin-Amgen Inc.
    • Laboratorio Quimico Farmaceutico Bergamo Ltd
    • Micromet, Inc. (CancerVax Corporation)
    • Nuevolution AB
    • Nuevolution A/S
    • Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
    • Saga Investments LLC
    • Tularik
UsernamePublicRestriction

Register